CHM is investigating CarT against solid tumour cancer, no peer...

CHM is investigating CarT against solid tumour cancer, no peer has got this to Work so far. And treating GBM, no peer can do this so far, apart from radiation and surgery. There is no effective SOC.

Market cap today is sub $aud15 million.

Considering the above, what market cap would reflect disease control, or partial response if we hear this next week? Remember no other biotech has been able to achieve either of those for GBM so far.

Also remember we have been told there are a handful of other solid tumour cancers this drug may be effective at targeting.

The market is a fickle place at the moment. We have seen recently that any buyer can push the price up. But we have also seen that any one seller, even of low amounts, can push the price down. So unless the announcement ignites lots of interest where the buy lines are supported, they price may still stagnant.

10 bags from here is sub $aud150 million. It would also put the options in the money. This would have been considered an incredibly low MC in the market 3yrs ago, Today it looks like a huge feat to achieve.

So the share price/ market cap may not truely represent potential value until we get into the 1b expansion trial with results.

This week is a derisk pivot point. We get data that supports that the drug either works or it doesn't. If it looks like it works, we have the expansion trial leading into an accelerated approval triall. To be at this point in a company Only a handful of years old is nearly unheard of. And to have a pipeline with two drugs hitting arms, and another almost ready to start hitting arms, at a market cap of sub $15 million is something i have never seen before.

The opportunity for this to be life changing for investors is huge.